DrugDashboards

bisoprolol fumarate and hydrochlorothiazide

bisoprolol fumarate and hydrochlorothiazide · HYDROCHLOROTHIAZIDE 6.25 mg/1; BISOPROLOL FUMARATE 5 mg/1 · Tablet · Oral · Bryant Ranch Prepack

NDC 71335-0595-01 · 30 TABLET in 1 BOTTLE, PLASTIC · ANDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 29300-0188-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.4009per unit
middle half $0.2403$0.5244 · 5,454 plans · Apr 1, 2026
Est. net of rebates
≈ $0.4009
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
99%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 15%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for bisoprolol fumarate and hydrochlorothiazide (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA079106
TE code
AB
Approval date
Jul 28, 2010
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of bisoprolol fumarate and hydrochlorothiazide (Tablet)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsBISOPROLOL FUMARATE 5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.BISOPROLOL FUMARATE 10 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.BISOPROLOL FUMARATE 5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.BISOPROLOL FUMARATE 2.5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackHYDROCHLOROTHIAZIDE 6.25 mg/1; BISOPROLOL FUMARATE 2.5 mg/1Aug 26, 2026Sep 2, 2026
Bryant Ranch PrepackHYDROCHLOROTHIAZIDE 6.25 mg/1; BISOPROLOL FUMARATE 5 mg/1Aug 26, 2026Sep 2, 2026
Marlex Pharmaceuticals, Inc.BISOPROLOL FUMARATE 10 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
Marlex Pharmaceuticals, Inc.BISOPROLOL FUMARATE 2.5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
Marlex Pharmaceuticals, Inc.BISOPROLOL FUMARATE 5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Sep 2, 2026
Unichem Pharmaceuticals (USA), Inc.HYDROCHLOROTHIAZIDE 6.25 mg/1; BISOPROLOL FUMARATE 5 mg/1Aug 26, 2026Sep 2, 2026
Unichem Pharmaceuticals (USA), Inc.HYDROCHLOROTHIAZIDE 6.25 mg/1; BISOPROLOL FUMARATE 10 mg/1Aug 26, 2026Sep 2, 2026
Unichem Pharmaceuticals (USA), Inc.HYDROCHLOROTHIAZIDE 6.25 mg/1; BISOPROLOL FUMARATE 2.5 mg/1Aug 26, 2026Sep 2, 2026
Bryant Ranch PrepackHYDROCHLOROTHIAZIDE 2.5 mg/1; BISOPROLOL FUMARATE 6.25 mg/1Jul 22, 2026Aug 19, 2026
Bryant Ranch PrepackHYDROCHLOROTHIAZIDE 5 mg/1; BISOPROLOL FUMARATE 6.25 mg/1Jul 22, 2026Aug 19, 2026
Unichem Pharmaceuticals (USA), Inc.HYDROCHLOROTHIAZIDE 10 mg/1; BISOPROLOL FUMARATE 6.25 mg/1Jul 22, 2026Aug 19, 2026
Unichem Pharmaceuticals (USA), Inc.HYDROCHLOROTHIAZIDE 2.5 mg/1; BISOPROLOL FUMARATE 6.25 mg/1Jul 22, 2026Aug 19, 2026
Unichem Pharmaceuticals (USA), Inc.HYDROCHLOROTHIAZIDE 5 mg/1; BISOPROLOL FUMARATE 6.25 mg/1Jul 22, 2026Aug 19, 2026
Bryant Ranch PrepackBISOPROLOL FUMARATE 5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Jul 15, 2026
Bryant Ranch PrepackBISOPROLOL FUMARATE 2.5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Jul 15, 2026
Unichem Pharmaceuticals (USA), Inc.BISOPROLOL FUMARATE 2.5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Jul 15, 2026
Unichem Pharmaceuticals (USA), Inc.BISOPROLOL FUMARATE 5 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Jul 15, 2026
Unichem Pharmaceuticals (USA), Inc.BISOPROLOL FUMARATE 10 mg/1; HYDROCHLOROTHIAZIDE 6.25 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "bisoprolol fumarate and hydrochlorothiazide — NDC 71335-0595-01," retrieved September 3, 2026, https://drugdashboards.com/drug/71335059501.

Free to cite with attribution — see how the data is put together.